Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...
Hosted on MSN6h
Boston Scientific (BSX) is a Great Momentum Stock: Should You Buy?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even ...
Boston Scientific Co. (NYSE:BSX) Given Consensus Recommendation of “Buy” by Brokerages
Boston Scientific Co. (NYSE:BSX – Get Free Report) has been given an average recommendation of “Buy” by the twenty-three ...
Boston Scientific remains bullish despite tariffs, with sales buoyed by Minnesota tech
Minnesota system treating atrial fibrillation helped sustain Boston Scientific’s streak of bullish results as the company ...
J.P. Morgan Remains a Buy on Boston Scientific (BSX)
In a report released yesterday, Robbie Marcus from J.P. Morgan maintained a Buy rating on Boston Scientific (BSX – Research Report), with a ...
Boston Scientific sees higher-than-expected 2025 profit on strong demand
Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.
FierceBiotech2d
Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year
Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...
Boston Scientific price target raised to $122 from $119 at Raymond James
Raymond James analyst Jayson Bedford raised the firm’s price target on Boston Scientific (BSX) to $122 from $119 and keeps a Strong Buy rating ...